Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04707235
Other study ID # ESCORT-HU Extension
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date August 21, 2020
Est. completion date August 21, 2025

Study information

Verified date June 2023
Source ADDMEDICA SASA
Contact Laura Thomas-bourgneuf
Phone +33 1 72 69 01 86
Email laura.thomas-bourgneuf@addmedica.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

As safety information pertaining to the long-term use of HU remains incomplete in spite of the first safety study (ESCORT-HU), an extension of the latter is proposed. ESCORT-HU Extension study aims at evaluating the long-term safety of Siklos® focusing on some questions regarding its safety when used in current practice in adults and paediatric patients treated with Siklos® and followed for up to 5 years. The study will focus on the following concerns : occurrence and incidence of malignancies, leg ulcers, male fertility impairment and serious unexpected AEs causally related to Siklos®.


Recruitment information / eligibility

Status Recruiting
Enrollment 2000
Est. completion date August 21, 2025
Est. primary completion date August 21, 2025
Accepts healthy volunteers No
Gender All
Age group 2 Years and older
Eligibility Inclusion Criteria: - Male or female patients with symptomatic SCD, - = 2 years old, - Treated with Siklos®, - Having been informed of the study by the investigator and consenting to participate, or whose parents or legal guardians are consenting for their child to participate. To allow risk evaluation, participants must belong at least to one of the subpopulations defined below: - Participants previously enrolled in ESCORT-HU who agree to participate in ESCORT-HU Extension study, - New participants with any of the following criteria: - history of HU treatment for more than 5 years or - prepubescent over 10 years of age for girls and 13 years of age for boys at enrolment, or - with history of leg ulcer, or - pregnant women without interruption of Siklos® 3 months before the beginning of the pregnancy or, - males treated with Siklos® whose partner is pregnant and without discontinuation of Siklos® 3 months before the beginning of the pregnancy.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Hydroxycarbamide
Patients, aged = 2 years old, with symptomatic SCD, treated with Siklos®.

Locations

Country Name City State
France Amiens - Picardie Hospital Adults Amiens
France Amiens Picardie Hospital Children Amiens
France Clinique de l'Europe Amiens Amiens
France Angers Hospital Adults Angers
France Angers Hospital Center Children Angers
France Robert Ballanger Hospital Adults Aulnay-sous-Bois
France Robert Ballanger Hospital Children Aulnay-sous-Bois
France Avicenne Hospital Adults Bobigny
France Jean Verdier Hospital Children Bondy
France Bordeaux Hospital Adults Bordeaux
France Bordeaux Hospital Children Bordeaux
France Ambroise Paré Hospital Children Boulogne-Billancourt
France Tours Regional University Hospital Center Adults Chambray-lès-Tours
France Estaing Hospital Children Clermont-Ferrand
France Louis Mourier Hospital Adults Colombes
France Louis Mourier Hospital Children Colombes
France Centre Hospitalier Sud Francilien Corbeil-Essonnes
France Sud Francilien Hospital Center Adults Corbeil-Essonnes
France Sud Oise Public Hospital Group Adults Creil
France Henri Mondor Hospital Adults Créteil
France Intercommunal Hospital Center of Créteil Adults and Children Créteil
France Dreux Hospital Center Children Dreux
France Gonesse Hospital Children Gonesse
France Marne-La-Vallée Hospital Center Children Jossigny
France Grenoble Hospital Adults La Tronche
France Grenoble Hospital Children La Tronche
France Bicêtre Hospital Adults Le Kremlin-Bicêtre
France Hôpital Bicêtre Le Kremlin-Bicêtre
France CH du Mans Le Mans
France Hôpital Saint-Vincent de Paul Lille
France Jeanne De Flandre Hospital Children Lille
France Hôpital Mère-Enfant - CHU de Limoges Limoges
France Edouard Herriot Hospital Adults Lyon
France Hematology and oncology institute Children Lyon
France Timone Hospital Adults Marseille
France Timone Hospital Children Marseille
France Meaux Hospital Center Adults Meaux
France Meaux Hospital Center Children Meaux
France Montpellier Hospital Children Montpellier
France St Eloi Hospital Adults Montpellier
France Emile Muller Hospital Adults Mulhouse
France Nantes Hospital Adults Nantes
France Nantes Hospital Children Nantes
France Nice Hospital Children Nice
France Orléans Hospital Adults Orléans
France Armand Trousseau Hospital Children Paris
France Georges Pompidou European Hospital Adults Paris
France Necker Hospital Adults Paris
France Necker Hospital Children Paris
France Robert Debré Hospital Children Paris
France Saint-Antoine Hospital Adults Paris
France Centre hospitalier Perpignan Perpignan
France Poitiers Hospital Adults Poitiers
France American Hospital Children Reims
France Reims Hospital Adults Reims
France Pontchaillou Hospital Adults Rennes
France Charles Nicolle Hospital Adults Rouen
France Rouen Hospital Children Rouen
France Yves Le Foll. Hospital Center Children Saint-Brieuc
France Delafontaine Hospital Center Adults Saint-Denis
France Delafontaine Hospital Center Children Saint-Denis
France Saint-Quentin Hospital Center Adults Saint-Quentin
France Hautepierre Hospital Children Strasbourg
France Children Hospital Toulouse
France Toulouse University Institute of cancer Adults Toulouse
France Clocheville Regional University Hospital Center Children Tours
France Nancy Hospital Children Vandoeuvre les nancy
France Versailles Hospital Center Children Versailles
French Guiana CH de Cayenne Cayenne
French Guiana Centre hospitalier de Kourou Children Kourou
French Guiana Centre Hospitalier de l'Ouest Guyanais Franck Joly Adults Saint-Laurent-du-Maroni
French Guiana Centre Hospitalier de l'Ouest Guyanais Franck Joly Children Saint-Laurent-du-Maroni
Germany Charité Hospital Children Berlin
Germany Düsseldorf Hospital Children Düsseldorf
Germany Freiburg Hospital Children Freiburg
Germany Hamburg Hospital Children Hamburg
Germany Koblenz Hospital Children Koblenz
Greece Laiko General Hospital Adults Athens
Guadeloupe Hôpital RICOU - CHU Pointe-à-Pitre Abymes Pointe-à-Pitre
Guadeloupe Hôpital RICOU - CHU Pointe-à-Pitre Abymes Children Pointe-à-Pitre
Italy AUO Policlinico di Modena Modena
Italy Napoli Hospital Children Napoli
Italy Padova Hospital Children Padova
Italy Verona Hospital Children Verona
Martinique CHU Fort de France Children Fort-de-France
Martinique CHU Martinique Adults Le Lamentin
Réunion CHU Sud Réunion Saint-Pierre

Sponsors (2)

Lead Sponsor Collaborator
ADDMEDICA SASA International Clinical Trials Association

Countries where clinical trial is conducted

France,  French Guiana,  Germany,  Greece,  Guadeloupe,  Italy,  Martinique,  Réunion, 

Outcome

Type Measure Description Time frame Safety issue
Primary Occurrence and incidence of the number of malignancies, leg ulcers, male fertility impairment and serious unexpected AEs causally related to Siklos® 5 years
Primary Occurrence and incidence of the number of leg ulcers 5 years
Primary Occurrence and incidence of male fertility impairment 5 years
Primary Occurrence and incidence of serious unexpected AEs causally related to Siklos® 5 years
Secondary Mean age of puberty Document changes in fertility status in males and females 5 years
Secondary Mean number of patients with the use of a contraception, incidence of the use of semen cryopreservation and of semen analysis performed Document changes in fertility status in males and females 5 years
Secondary Incidence of the use of semen cryopreservation and of semen analysis performed Document changes in fertility status in males and females 5 years
Secondary Incidence of semen analysis performed Document changes in fertility status in males and females 5 years
Secondary Management of Siklos® during pregnancy and outcome of pregnancy following exposure at the time of conception or at any time during the pregnancy Outcome of pregnancies Following exposure to Siklos® at the time of conception (in participant and participant's partner) or at any time during the pregnancy 5 years
Secondary Frequency and reason for temporary or permanent discontinuations of Siklos® Potential barriers to the compliance to the prescription of Siklos 5 years
Secondary Number of switch and combination with alternative treatment 5 years
Secondary Measure of quality of life with SF12 questionnaire Quality of life for adults SCD patients 5 years
See also
  Status Clinical Trial Phase
Completed NCT02227472 - Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease
Recruiting NCT06301893 - Uganda Sickle Surveillance Study (US-3)
Recruiting NCT04398628 - ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Completed NCT02522104 - Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH) Phase 4
Recruiting NCT04688411 - An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease N/A
Terminated NCT03615924 - Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease Phase 3
Recruiting NCT03937817 - Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Completed NCT04917783 - Health Literacy - Neurocognitive Screening in Pediatric SCD N/A
Completed NCT04134299 - To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease N/A
Completed NCT02580565 - Prevalence of Problematic Use of Equimolar Mixture of Oxygen and Nitrous Oxide and Analgesics in the Sickle-cell Disease
Recruiting NCT04754711 - Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition N/A
Completed NCT04388241 - Preliminary Feasibility and Efficacy of Behavioral Intervention to Reduce Pain-Related Disability in Pediatric SCD N/A
Recruiting NCT05431088 - A Phase 2/3 Study in Adult and Pediatric Participants With SCD Phase 2/Phase 3
Completed NCT01158794 - Genes Influencing Iron Overload State
Recruiting NCT03027258 - Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome N/A
Withdrawn NCT02960503 - Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease Phase 1/Phase 2
Withdrawn NCT02630394 - A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease Phase 1
Completed NCT02620488 - A Brief Laboratory-Based Hypnosis Session for Pain in Sickle Cell Disease N/A
Completed NCT02567682 - Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects Phase 1
Completed NCT02567695 - A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects Phase 1